ArticleInflammopharmacology2026
Selenium and probiotics co-supplementation: A scoping review of clinical evidence.
Article in Inflammopharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundSelenium and probiotics have been individually recognized for their antioxidant, anti-inflammatory, and immune-modulating properties. However, the potential synergistic effects of their co-supplementation in human health remain minimally investigated. This scoping review aimed to summarize the current evidence on the impact of co-supplementation with selenium and probiotics.
methodsA comprehensive literature search was conducted across PubMed, Scopus, Embase, and Web of Science databases to identify clinical trials investigating the effects of selenium and probiotics co-supplementation. Eligible studies included randomized controlled trials (RCTs) and non-randomized clinical trials assessing clinical, metabolic, inflammatory, oxidative stress, and immune-related outcomes.
resultsTen clinical studies met the inclusion criteria, including populations with polycystic ovary syndrome, Alzheimer’s disease, schizophrenia, leukemia, gestational diabetes, elderly nursing home residents, and ICU patients with stage I–II bedsores. Co-supplementation was associated with changes in glycemic indices (fasting plasma glucose, insulin, HOMA-IR, QUICKI), selected lipid parameters (triglycerides, total cholesterol, LDL cholesterol), oxidative stress markers (total antioxidant capacity, glutathione, malondialdehyde), and inflammatory markers, particularly high-sensitivity C-reactive protein. Studies also reported improvements in mental health scores, cognitive function (MMSE), and immune-related markers including adhesion molecules. Gene expression changes, including TNF-α and PPAR-γ, were reported in limited studies. Overall, co-supplementation was well tolerated, with no serious adverse events reported.
conclusionsSelenium and probiotics co-supplementation may provide beneficial effects on metabolic regulation, oxidative stress, and inflammation-related conditions. However, heterogeneity in study design, probiotics’ strains, selenium dosage, and treatment duration limits firm conclusions. Larger, well-designed randomized controlled trials with long-term follow-up are needed.
Indexed as
Identifiers
41915110What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.